Antifungal effect of hydroethanolic extract of Fridericia chica (Bonpl.) L. G. Lohmann leaves and its therapeutic use in a vulvovaginal candidosis model - 17/08/22
, Marcelo Gonzaga Freitas Araújo b, Júlio César Moreira Brito c, Rachel Oliveira Castilho d, Valbert Nascimento Cardoso a, Simone Odília Antunes Fernandes a, ⁎Abstract |
Vulvovaginal candidosis (VVC) is one of the most frequent causes of gynecological consultations. Therefore, the development of new antifungal therapies against VVC is relevant. In this context, the leaves of Fridericia chica (Bonpl.) L. G. Lohmann are considered a therapeutic alternative since they are traditionally used in VVC therapy. However, no scientific evidence has supported this use against fungal vaginal infections. Then, we aimed to characterize the antifungal effect of a hydroethanolic extract of F. chica leaves (HEFc) and evaluate the therapeutic potential of this extract in a VVC model. HEFc inhibited the growth of C. albicans (256–1,204 µg/mL) and C. krusei (512 µg/mL) in vitro. HEFc inhibited yeast-to-hypha transition in C. albicans and has a low ability to induce resistance in this species. Intravaginal use of the HEFc at 50 mg/mL causes mycological cure in animals with VVC after 6 days of treatment, similar to the effect observed for the commercial antifungal nystatin. These results support the traditional use of F. chica leaves as a topical therapeutic option to treat VVC.
El texto completo de este artículo está disponible en PDF.Keywords : Herbal medicine, Candidiasis, Gynecological infections, Azole-resistant Candida albicans, Antifungal development
Abbreviations : VVC, NAC, HEFc, MIC, MBC, FBS, SDB, SDA, CFU, ANOVA, Y-H
Esquema
Vol 32 - N° 3
Artículo 101255- août 2022 Regresar al número
Artículo precedente
- Clinical profile and outcome of non-HIV-infected patients with cryptococcal meningitis and malignancy
- Xiaofeng Xu, Liping Cao, Yijie Wang, Jia Liu, Qing Dong, Chunling Liang, Ying Jiang, Fuhua Peng
- A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails
- M. Ehrensberger, C.W.C. Boal, J. Brennan, J. Barrett, J. Makarus, S. Callanan, E. Spillane, T. Patton
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?